Mergertechnology Staff

Amgen, one of the world’s leading biotechnology companies, recently filed a complaint for patent infringement under the Biologics Price Competition and Innovation Act (BPCIA) against Mylan. According to Big Molecule Watch, the litigation claims that “certain actions by Mylan during the patent dance exchanges prejudiced Amgen and/or violated the BPCIA.” Amgen alleges that Mylan “materially […]